Memantine and acetylcholinesterase inhibitor treatment in cases of CDR 0.5 or questionable impairment. - Wikidata - awgldk - TriplyDB

Memantine and acetylcholinesterase inhibitor treatment in cases of CDR 0.5 or questionable impairment.

Memantine and acetylcholinesterase inhibitor treatment in cases of CDR 0.5 or questionable impairment.

http://www.wikidata.org/entity/Q33684234

about

Effects of the coexistence of late-life depression and mild cognitive impairment on white matter microstructure Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia Late-life depression, mild cognitive impairment and hippocampal functional network architecture.Recruitment methods for United States Alzheimer disease prevention trials.Putative Dementia Cases Fluctuate as a Function of Mini-Mental State Examination Cut-Off Points.Patterns and Determinants of Dementia Pharmacotherapy in a Population-Based Cohort of Home Care Clients Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment

P2860

Q35596915-E75369AC-8C66-4F13-9A9A-5276732E49AB Q36177038-39C00132-E050-45C2-9D23-3D8CDBC15C07 Q37272637-EC18110D-1D0B-47A8-ADBD-6BA3FA0F46C2 Q38002365-D1B2040A-F34B-4D5F-ACA2-F79482961CAC Q47575764-20CB2DAA-68B8-43B8-9C6E-E0261B3832A4 Q57244256-189493D2-8BCC-4DC8-B44A-12DF2EB51AE9 Q58698317-8517C19B-575C-482A-8416-61F522A2B5DF

P2860

Memantine and acetylcholinesterase inhibitor treatment in cases of CDR 0.5 or questionable impairment.

http://www.wikidata.org/entity/Q33684234

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Memantine and acetylcholineste ...... .5 or questionable impairment.

@ast

Memantine and acetylcholineste ...... .5 or questionable impairment.

@en

type

label

Memantine and acetylcholineste ...... .5 or questionable impairment.

@ast

Memantine and acetylcholineste ...... .5 or questionable impairment.

@en

prefLabel

Memantine and acetylcholineste ...... .5 or questionable impairment.

@ast

Memantine and acetylcholineste ...... .5 or questionable impairment.

@en

P1433

Q33684234-67BDE829-28A0-449C-A4D7-9EA56999C93C

P1476

Q33684234-1DCB28B5-2C8C-4375-8E08-9E1919D15A6C

P2093

Q33684234-3425D5FA-FA3E-41DF-ABA9-EE9A7F8B23A6

Q33684234-6712D61E-CD52-4943-87A3-C69CBCDBC185

Q33684234-ABBB60E5-D38F-4E84-A642-B050E2192BB4

Q33684234-C2B361CB-7E23-427E-B711-1B35754C9703

P2860

Q33684234-02BC56A5-9F47-4E77-BDB4-A391DA1213E8

Q33684234-03B8C8C6-8E0A-4CE5-852D-B1F8FF6DA521

Q33684234-059F0584-6326-43D8-87EE-90EFA6C373ED

Q33684234-106B6184-6F32-40ED-9778-1EA42A3D6427

Q33684234-1D648F80-EE8D-400D-8EDA-265ED2803577

Q33684234-1F009D6F-E8A6-4DFB-9910-B698CDFACF57

Q33684234-221CD5AE-2B60-4D96-BDF8-06FDC5B8BC88

Q33684234-2F16A3EA-62DC-4228-BEBF-C2E68CAFE154

Q33684234-2F6EB71C-FDE2-485B-8961-08C4D6AE4168

Q33684234-30ECEBD7-8594-4DED-AFEF-A2242963BD89

P304

Q33684234-B6188A68-96A3-4AF0-BEF0-1D4625678C45

P31

Q33684234-23BC7C78-0214-4298-8E63-1E5202AC139C

P356

Q33684234-E1B2BE0C-EF60-4DF0-AB94-6ED38067E329

P433

Q33684234-3E2B1E86-D9C0-4F8B-BDDF-0F1FFC0D1718

P478

Q33684234-26AF78F2-A822-4624-B4D4-2B486C3980B2

P577

Q33684234-9F8468AF-64DE-4593-A7D0-1873DBBFC2E6

P5875

Q33684234-122A2F78-5BAF-41F6-A668-CB87DBB3CDFE

P698

Q33684234-5ED4B20F-97A9-4B69-99D8-2F13183CA389

P932

Q33684234-7DCE5F27-D3B7-4A67-A5F5-9BD074FA885D

P356

P1433

Journal of Alzheimer's Disease

P1476

Memantine and acetylcholineste ...... .5 or questionable impairment.

@en

P2093

Alan J Lerner

http://www.w3.org/2001/XMLSchema#string

Kathleen A Smyth

http://www.w3.org/2001/XMLSchema#string

McKee J McClendon

http://www.w3.org/2001/XMLSchema#string

Santiago Hernandez

http://www.w3.org/2001/XMLSchema#string

P2860

“Mini-mental state”

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Mild cognitive impairment: clinical characterization and outcome

Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents

Development and validation of a geriatric depression screening scale: a preliminary report

The Clinical Dementia Rating (CDR): current version and scoring rules

Antidepressant effects of ketamine in depressed patients

Violations of exhibiting and FDA rules at an American Psychiatric Association annual meeting.

The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers.

Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease

P304

577-583

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3233/JAD-2009-0994

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24191718

http://www.w3.org/2001/XMLSchema#string

P698

19276552

http://www.w3.org/2001/XMLSchema#string

P932

2827605

http://www.w3.org/2001/XMLSchema#string